Gut check: could your microbiome predict cancer treatment success?
NCT ID NCT07551765
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how diet and gut bacteria affect treatment outcomes in women with early-stage triple-negative breast cancer. Researchers will collect stool, blood, and tumor samples from 300 participants before, during, and after chemotherapy and immunotherapy. The goal is to see if changes in the gut microbiome can predict whether the cancer disappears completely after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors predict which patients will respond best to treatment and potentially guide dietary recommendations to improve outcomes.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test a new therapy, and results may take years to translate into clinical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC), EARLY SETTING are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts Health NHS Trust
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.